Tamiflu touted for child use

Nov 16, 2007

The maker of the anti-viral Tamiflu said the drug is effective for treatment and prevention of influenza in young children.

Data presented at the World Society for Pediatric Infectious Disease meeting in Bangkok this week said Tamiflu (oseltamivir) significantly reduces illness severity and duration of influenza in children ages 1 and older, particularly if given within 24 hours of symptom onset, Roche pharmaceuticals said Thursday in a release.

Roche pharmaceuticals said it will offer child-sized Tamiflu capsules of 30 mg and 45 mg doses to provide easier and more convenient dosing by parents.

The company said Tamiflu was shown to reduce influenza severity by 52 percent, and illness duration was reduced by 34 percent if treatment was started within 24 hours of onset.

Copyright 2007 by United Press International

Explore further: Drug for rare blood disorder developed at Penn receives orphan drug status from EU

add to favorites email to friend print save as pdf

Related Stories

New research assesses use of Tamiflu, Relenza to prevent flu

Aug 03, 2009

Two common anti-influenza drugs — Relenza and Tamiflu — appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine. However, ...

TGen seeks emergency FDA approval of new swine flu test

Oct 29, 2009

The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of ...

Recommended for you

Expression of privilege in vaccine refusal

1 hour ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments : 0